> top > docs > PubMed:31213813 > annotations

PubMed:31213813 JSONTXT

Annnotations TAB JSON ListView MergeView

GoldHamster

Id Subject Object Predicate Lexical cue
T1 18-21 CVCL_1K15 denotes HER
T2 18-22 PR:P04626 denotes HER2
T3 18-22 PR:000002082 denotes HER2
T4 18-22 PR:Q03557 denotes HER2
T5 18-22 PR:P34708 denotes HER2
T6 18-22 PR:Q5AK64 denotes HER2
T8 23-30 SO:0000031 denotes aptamer
T7 23-30 CHEBI:140488 denotes aptamer
T9 67-73 D012822 denotes silica
T10 67-73 CHEBI:30563 denotes silica
T11 67-73 D012822 denotes silica
T12 92-96 CHEBI:23888 denotes drug
T13 159-162 CVCL_1K15 denotes HER
T14 159-163 PR:P04626 denotes HER2
T15 159-163 PR:000002082 denotes HER2
T16 159-163 PR:Q03557 denotes HER2
T17 159-163 PR:P34708 denotes HER2
T18 159-163 PR:Q5AK64 denotes HER2
T19 173-179 UBERON:0000310 denotes breast
T20 173-186 D001943 denotes breast cancer
T21 173-186 D001943 denotes breast cancer
T22 231-237 CHEBI:52214 denotes ligand
T23 231-237 GO:0005488 denotes ligand
T24 295-300 D006801 denotes human
T25 295-335 C508053 denotes human epidermal growth factor receptor-2
T26 295-335 C508053 denotes human epidermal growth factor receptor-2
T27 301-317 UBERON:0000021 denotes epidermal growth
T31 301-324 GO:0005154 denotes epidermal growth factor
T32 301-333 Q01279 denotes epidermal growth factor receptor
T33 301-333 P0CY46 denotes epidermal growth factor receptor
T34 301-333 P55245 denotes epidermal growth factor receptor
T35 301-333 P00533 denotes epidermal growth factor receptor
T36 301-333 P04412 denotes epidermal growth factor receptor
T38 301-333 P13387 denotes epidermal growth factor receptor
T39 301-333 PR:000006933 denotes epidermal growth factor receptor
T45 337-340 CVCL_1K15 denotes HER
T46 337-341 PR:P04626 denotes HER2
T47 337-341 PR:000002082 denotes HER2
T48 337-341 PR:Q03557 denotes HER2
T49 337-341 PR:P34708 denotes HER2
T50 337-341 PR:Q5AK64 denotes HER2
T51 418-431 SO:0000199 denotes translocation
T52 435-438 CVCL_1K15 denotes HER
T53 435-439 PR:P04626 denotes HER2
T54 435-439 PR:000002082 denotes HER2
T55 435-439 PR:Q03557 denotes HER2
T56 435-439 PR:P34708 denotes HER2
T57 435-439 PR:Q5AK64 denotes HER2
T58 488-491 CVCL_1K15 denotes HER
T59 488-492 PR:P04626 denotes HER2
T60 488-492 PR:000002082 denotes HER2
T61 488-492 PR:Q03557 denotes HER2
T62 488-492 PR:P34708 denotes HER2
T63 488-492 PR:Q5AK64 denotes HER2
T64 502-520 GO:0008283 denotes cell proliferation
T65 507-520 UBERON:2000098 denotes proliferation
T66 533-542 GO:0097194 denotes apoptosis
T67 533-542 GO:0006915 denotes apoptosis
T68 616-626 CHEBI:48706 denotes antagonist
T72 666-685 CHEBI:50828 denotes silica nanoparticle
T74 687-690 PR:O35763 denotes MSN
T76 687-690 PR:000003008 denotes MSN
T77 687-690 PR:P26041 denotes MSN
T78 687-690 PR:P26038 denotes MSN
T75 687-690 CVCL_9882 denotes MSN
T79 698-702 CHEBI:23888 denotes drug
T80 723-726 CVCL_1K15 denotes HER
T81 723-727 PR:P04626 denotes HER2
T82 723-727 PR:000002082 denotes HER2
T83 723-727 PR:Q03557 denotes HER2
T84 723-727 PR:P34708 denotes HER2
T85 723-727 PR:Q5AK64 denotes HER2
T86 737-743 UBERON:0000310 denotes breast
T87 737-750 D001943 denotes breast cancer
T88 737-750 D001943 denotes breast cancer
T90 800-807 SO:0000031 denotes aptamer
T89 800-807 CHEBI:140488 denotes aptamer
T91 2-14 CHEBI:23456 denotes dual-functio
T92 858-864 SO:0000146 denotes capped
T95 865-876 3639 denotes doxorubicin
T93 865-876 D004317 denotes doxorubicin
T94 865-876 CHEBI:64816 denotes doxorubicin
T96 865-876 CHEBI:28748 denotes doxorubicin
T97 865-876 D004317 denotes doxorubicin
T98 901-907 D012822 denotes silica
T99 901-907 CHEBI:30563 denotes silica
T100 901-907 D012822 denotes silica
T101 908-921 CHEBI:50803 denotes nanoparticles
T102 930-933 PR:O35763 denotes MSN
T104 930-933 PR:000003008 denotes MSN
T105 930-933 PR:P26041 denotes MSN
T106 930-933 PR:P26038 denotes MSN
T103 930-933 CVCL_9882 denotes MSN
T107 999-1002 CVCL_1K15 denotes HER
T108 999-1003 PR:P04626 denotes HER2
T109 999-1003 PR:000002082 denotes HER2
T110 999-1003 PR:Q03557 denotes HER2
T111 999-1003 PR:P34708 denotes HER2
T112 999-1003 PR:Q5AK64 denotes HER2
T113 1020-1023 PR:O35763 denotes MSN
T115 1020-1023 PR:000003008 denotes MSN
T116 1020-1023 PR:P26041 denotes MSN
T117 1020-1023 PR:P26038 denotes MSN
T114 1020-1023 CVCL_9882 denotes MSN
T118 1039-1052 C031000 denotes benzimidazole
T119 1039-1052 C031000 denotes benzimidazole
T120 1039-1052 CHEBI:41275 denotes benzimidazole
T121 1039-1052 CHEBI:36622 denotes benzimidazole
T122 1054-1057 PR:O35763 denotes MSN
T124 1054-1057 PR:000003008 denotes MSN
T125 1054-1057 PR:P26041 denotes MSN
T126 1054-1057 PR:P26038 denotes MSN
T123 1054-1057 CVCL_9882 denotes MSN
T127 1151-1162 D004317 denotes doxorubicin
T128 1151-1162 CHEBI:64816 denotes doxorubicin
T130 1151-1162 CHEBI:28748 denotes doxorubicin
T131 1151-1162 D004317 denotes doxorubicin
T129 1151-1162 3639 denotes doxorubicin
T132 1172-1184 CHEBI:23456 denotes cyclodextrin
T133 1205-1215 111938 denotes gatekeeper
T134 1261-1264 CVCL_1K15 denotes HER
T135 1261-1265 PR:P04626 denotes HER2
T136 1261-1265 PR:000002082 denotes HER2
T137 1261-1265 PR:Q03557 denotes HER2
T138 1261-1265 PR:P34708 denotes HER2
T139 1261-1265 PR:Q5AK64 denotes HER2
T140 1371-1374 PR:000016500 denotes TEM
T141 1371-1374 Q9H2S6 denotes TEM
T144 1371-1374 Q9EP64 denotes TEM
T145 1371-1374 Q9ESC2 denotes TEM
T142 1371-1374 CVCL_E844 denotes TEM
T143 1371-1374 GO:0097197 denotes TEM
T146 1371-1374 CHEBI:27919 denotes TEM
T147 1379-1382 PR:Q8JZM4 denotes BET
T148 1379-1382 PR:Q8NFT8 denotes BET
T149 1379-1382 PR:000006599 denotes BET
T150 1379-1382 CHEBI:17750 denotes BET
T151 1421-1424 PR:O35763 denotes MSN
T153 1421-1424 PR:000003008 denotes MSN
T154 1421-1424 PR:P26041 denotes MSN
T155 1421-1424 PR:P26038 denotes MSN
T152 1421-1424 CVCL_9882 denotes MSN
T156 1440-1453 CHEBI:50803 denotes nanoparticles
T157 1514-1517 PR:O35763 denotes MSN
T159 1514-1517 PR:000003008 denotes MSN
T160 1514-1517 PR:P26041 denotes MSN
T161 1514-1517 PR:P26038 denotes MSN
T158 1514-1517 CVCL_9882 denotes MSN
T167 1583-1586 CVCL_1K15 denotes HER
T168 1583-1587 PR:P04626 denotes HER2
T169 1583-1587 PR:000002082 denotes HER2
T170 1583-1587 PR:Q03557 denotes HER2
T171 1583-1587 PR:P34708 denotes HER2
T172 1583-1587 PR:Q5AK64 denotes HER2
T173 1597-1608 GO:0006897 denotes endocytosis
T174 1635-1638 CVCL_1K15 denotes HER
T175 1635-1639 PR:P04626 denotes HER2
T176 1635-1639 PR:000002082 denotes HER2
T177 1635-1639 PR:Q03557 denotes HER2
T178 1635-1639 PR:P34708 denotes HER2
T179 1635-1639 PR:Q5AK64 denotes HER2
T180 1649-1654 CVCL_0033 denotes SKBR3
T181 1666-1669 CVCL_1K15 denotes HER
T182 1666-1670 PR:P04626 denotes HER2
T183 1666-1670 PR:000002082 denotes HER2
T184 1666-1670 PR:Q03557 denotes HER2
T185 1666-1670 PR:P34708 denotes HER2
T186 1666-1670 PR:Q5AK64 denotes HER2
T188 1680-1684 CVCL_0031 denotes MCF7
T189 1692-1695 PR:O35763 denotes MSN
T191 1692-1695 PR:000003008 denotes MSN
T192 1692-1695 PR:P26041 denotes MSN
T193 1692-1695 PR:P26038 denotes MSN
T190 1692-1695 CVCL_9882 denotes MSN
T194 1733-1739 GO:0098657 denotes uptake
T195 1733-1739 GO:0098739 denotes uptake
T196 1774-1779 CVCL_0033 denotes SKBR3
T197 1803-1806 PR:O35763 denotes MSN
T199 1803-1806 PR:000003008 denotes MSN
T200 1803-1806 PR:P26041 denotes MSN
T201 1803-1806 PR:P26038 denotes MSN
T198 1803-1806 CVCL_9882 denotes MSN
T202 1855-1865 CHEBI:36976 denotes nucleotide
T203 1866-1874 SO:0000001 denotes sequence
T204 1891-1904 GO:0005622 denotes intracellular
T205 2000-2003 CVCL_1K15 denotes HER
T206 2000-2004 PR:P04626 denotes HER2
T207 2000-2004 PR:000002082 denotes HER2
T208 2000-2004 PR:Q03557 denotes HER2
T209 2000-2004 PR:P34708 denotes HER2
T210 2000-2004 PR:Q5AK64 denotes HER2
T211 2082-2085 PR:O35763 denotes MSN
T213 2082-2085 PR:000003008 denotes MSN
T214 2082-2085 PR:P26041 denotes MSN
T215 2082-2085 PR:P26038 denotes MSN
T212 2082-2085 CVCL_9882 denotes MSN
T216 2109-2112 CVCL_1K15 denotes HER
T217 2109-2113 PR:P04626 denotes HER2
T218 2109-2113 PR:000002082 denotes HER2
T219 2109-2113 PR:Q03557 denotes HER2
T220 2109-2113 PR:P34708 denotes HER2
T221 2109-2113 PR:Q5AK64 denotes HER2
T222 2189-2193 CHEBI:23888 denotes drug
T223 2249-2252 CVCL_1K15 denotes HER
T224 2249-2253 PR:P04626 denotes HER2
T225 2249-2253 PR:000002082 denotes HER2
T226 2249-2253 PR:Q03557 denotes HER2
T227 2249-2253 PR:P34708 denotes HER2
T228 2249-2253 PR:Q5AK64 denotes HER2
T229 2396-2399 CVCL_1K15 denotes HER
T230 2396-2400 PR:P04626 denotes HER2
T231 2396-2400 PR:000002082 denotes HER2
T232 2396-2400 PR:Q03557 denotes HER2
T233 2396-2400 PR:P34708 denotes HER2
T234 2396-2400 PR:Q5AK64 denotes HER2

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 194-543 DRI_Outcome denotes Purpose: As well as functioning as a ligand that is selectively internalized by cells overexpressing human epidermal growth factor receptor-2 (HER2), HApt can exert cytotoxic effects by inducing cross-linking and subsequent translocation of HER2 to cytoplasmic vesicles, such downregulation of HER2 inhibits cell proliferation and induces apoptosis.
T2 544-751 DRI_Challenge denotes We aimed to exploit the potential of HApt as both a targeting agent and antagonist to maximize the efficacy of mesoporous silica nanoparticle (MSN)-based drug release systems for HER2-positive breast cancer.
T3 752-794 DRI_Background denotes Materials and methods: We fabricated novel
T4 851-1019 DRI_Background denotes (β-CD)-capped doxorubicin (DOX)-loaded mesoporous silica nanoparticles (termed MSN-BM/CD-HApt@DOX) for targeted delivery and selective targeting of HER2-positive cells.
T5 1020-1038 REPLACED denotes MSN-functionalized
T6 1053-1169 DRI_Background denotes (MSN-BM) was used to load and achieve pH stimuli-responsive release of the chemotherapeutic agent doxorubicin (DOX).
T7 1170-1308 DRI_Approach denotes β-cyclodextrin was introduced as a gatekeeper for encapsulated DOX and HApt as a selective HER2-targeting moiety and biotherapeutic agent.
T8 1455-1513 DRI_Background denotes In vitro release assays verified pH-sensitive DOX release.
T9 1514-1665 DRI_Background denotes MSN-BM/CD-HApt@DOX (relative DOX concentration, 3.6 μg/mL) underwent HER2-mediated endocytosis and was more cytotoxic to HER2-positive SKBR3 cells than
T10 1685-1691 DRI_Background denotes cells.
T11 1692-1881 DRI_Outcome denotes MSN-BM/CD-HApt@DOX also exhibited better uptake and stronger growth inhibition in SKBR3 cells than the control MSN-BM/CD-NCApt@DOX functionalized with a scrambled nucleotide sequence on CD.
T12 1882-2069 DRI_Background denotes Overall, intracellular delivery of DOX and the biotherapeutic agent HApt resulted in synergistic cytotoxic effects in HER2-positive cancer cells in comparison to either DOX or HApt alone.
T13 2070-2284 DRI_Outcome denotes Conclusion: MSN-BM/CD-HApt@DOX enables HER2-mediated targeting and biotherapeutic effects as well as pH-responsive DOX drug release, resulting in synergistic cytotoxic effects in HER2-overexpressing cells in vitro.
T14 2285-2417 DRI_Outcome denotes This novel nanocarrier could potentially enable specific targeting to improve the efficacy of chemotherapy for HER2-positive cancer.

Goldhamster2_Cellosaurus

Id Subject Object Predicate Lexical cue
T1 0-1 CVCL_6479|Finite_cell_line|Mus musculus denotes A
T2 46-55 CVCL_C410|Hybridoma|Mus musculus denotes activated
T3 180-186 CVCL_E025|Induced_pluripotent_stem_cell|Homo sapiens denotes cancer
T4 229-230 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T5 544-546 CVCL_5M23|Cancer_cell_line|Mesocricetus auratus denotes We
T6 594-595 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T7 687-690 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T8 744-750 CVCL_E025|Induced_pluripotent_stem_cell|Homo sapiens denotes cancer
T9 775-777 CVCL_5M23|Cancer_cell_line|Mesocricetus auratus denotes We
T10 854-856 CVCL_5731|Spontaneously_immortalized_cell_line|Mus musculus denotes CD
T11 854-856 CVCL_W955|Cancer_cell_line|Homo sapiens denotes CD
T12 930-933 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T13 934-936 CVCL_E481|Transformed_cell_line|Homo sapiens denotes BM
T14 934-936 CVCL_S926|Spontaneously_immortalized_cell_line|Lates calcarifer denotes BM
T15 937-939 CVCL_5731|Spontaneously_immortalized_cell_line|Mus musculus denotes CD
T16 937-939 CVCL_W955|Cancer_cell_line|Homo sapiens denotes CD
T17 1020-1023 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T18 1054-1057 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T19 1058-1060 CVCL_E481|Transformed_cell_line|Homo sapiens denotes BM
T20 1058-1060 CVCL_S926|Spontaneously_immortalized_cell_line|Lates calcarifer denotes BM
T21 1203-1204 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T22 1249-1250 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T23 1359-1361 CVCL_4203|Spontaneously_immortalized_cell_line|Lithobates catesbeiana denotes FT
T24 1362-1364 CVCL_ZD54|Transformed_cell_line|Homo sapiens denotes IR
T25 1371-1374 CVCL_E844|Transformed_cell_line|Homo sapiens denotes TEM
T26 1421-1424 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T27 1425-1427 CVCL_E481|Transformed_cell_line|Homo sapiens denotes BM
T28 1425-1427 CVCL_S926|Spontaneously_immortalized_cell_line|Lates calcarifer denotes BM
T29 1428-1430 CVCL_5731|Spontaneously_immortalized_cell_line|Mus musculus denotes CD
T30 1428-1430 CVCL_W955|Cancer_cell_line|Homo sapiens denotes CD
T31 1514-1517 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T32 1518-1520 CVCL_E481|Transformed_cell_line|Homo sapiens denotes BM
T33 1518-1520 CVCL_S926|Spontaneously_immortalized_cell_line|Lates calcarifer denotes BM
T34 1521-1523 CVCL_5731|Spontaneously_immortalized_cell_line|Mus musculus denotes CD
T35 1521-1523 CVCL_W955|Cancer_cell_line|Homo sapiens denotes CD
T36 1569-1571 CVCL_F566|Transformed_cell_line|Homo sapiens denotes mL
T37 1569-1571 CVCL_W799|Cancer_cell_line|Homo sapiens denotes mL
T38 1649-1654 CVCL_0033|Cancer_cell_line|Homo sapiens denotes SKBR3
T39 1680-1684 CVCL_0031|Cancer_cell_line|Homo sapiens denotes MCF7
T40 1692-1695 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T41 1696-1698 CVCL_E481|Transformed_cell_line|Homo sapiens denotes BM
T42 1696-1698 CVCL_S926|Spontaneously_immortalized_cell_line|Lates calcarifer denotes BM
T43 1699-1701 CVCL_5731|Spontaneously_immortalized_cell_line|Mus musculus denotes CD
T44 1699-1701 CVCL_W955|Cancer_cell_line|Homo sapiens denotes CD
T45 1774-1779 CVCL_0033|Cancer_cell_line|Homo sapiens denotes SKBR3
T46 1803-1806 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T47 1807-1809 CVCL_E481|Transformed_cell_line|Homo sapiens denotes BM
T48 1807-1809 CVCL_S926|Spontaneously_immortalized_cell_line|Lates calcarifer denotes BM
T49 1810-1812 CVCL_5731|Spontaneously_immortalized_cell_line|Mus musculus denotes CD
T50 1810-1812 CVCL_W955|Cancer_cell_line|Homo sapiens denotes CD
T51 1843-1844 CVCL_6479|Finite_cell_line|Mus musculus denotes a
T52 1878-1880 CVCL_5731|Spontaneously_immortalized_cell_line|Mus musculus denotes CD
T53 1878-1880 CVCL_W955|Cancer_cell_line|Homo sapiens denotes CD
T54 2014-2020 CVCL_E025|Induced_pluripotent_stem_cell|Homo sapiens denotes cancer
T55 2082-2085 CVCL_9882|Cancer_cell_line|Homo sapiens denotes MSN
T56 2086-2088 CVCL_E481|Transformed_cell_line|Homo sapiens denotes BM
T57 2086-2088 CVCL_S926|Spontaneously_immortalized_cell_line|Lates calcarifer denotes BM
T58 2089-2091 CVCL_5731|Spontaneously_immortalized_cell_line|Mus musculus denotes CD
T59 2089-2091 CVCL_W955|Cancer_cell_line|Homo sapiens denotes CD
T60 2410-2416 CVCL_E025|Induced_pluripotent_stem_cell|Homo sapiens denotes cancer